Several other equities research analysts have also recently commented on RVNC. Zacks Investment Research cut Revance Therapeutics from a buy rating to a hold rating in a research note on Friday, September 15th. Cantor Fitzgerald reissued a buy rating and issued a $50.00 price target on shares of Revance Therapeutics in a research note on Tuesday, September 26th. Piper Jaffray Companies reaffirmed a buy rating and set a $28.00 target price on shares of Revance Therapeutics in a research report on Friday, October 27th. Mizuho started coverage on Revance Therapeutics in a research report on Thursday, November 16th. They set a buy rating and a $37.00 target price for the company. Finally, Barclays started coverage on Revance Therapeutics in a research report on Monday, November 27th. They set an overweight rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. Revance Therapeutics has a consensus rating of Buy and a consensus price target of $43.11.
Shares of Revance Therapeutics (RVNC) traded up $0.15 during midday trading on Tuesday, hitting $33.95. The company had a trading volume of 397,100 shares, compared to its average volume of 490,850. The company has a market cap of $1,050.00, a PE ratio of -8.91 and a beta of 1.62. Revance Therapeutics has a 1-year low of $18.00 and a 1-year high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.64) EPS. analysts expect that Revance Therapeutics will post -3.73 EPS for the current fiscal year.
In other news, CEO L Daniel Browne sold 7,662 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $26.16, for a total transaction of $200,437.92. Following the completion of the transaction, the chief executive officer now directly owns 140,788 shares in the company, valued at $3,683,014.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Lauren P. Silvernail sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $26.83, for a total value of $268,300.00. Following the transaction, the chief financial officer now owns 59,006 shares of the company’s stock, valued at $1,583,130.98. The disclosure for this sale can be found here. Insiders have sold 25,262 shares of company stock valued at $658,282 in the last ninety days. Company insiders own 18.86% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Revance Therapeutics by 7.3% during the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after buying an additional 63,505 shares during the last quarter. QS Investors LLC acquired a new position in shares of Revance Therapeutics during the second quarter worth approximately $1,564,000. Northern Trust Corp lifted its holdings in shares of Revance Therapeutics by 19.9% during the second quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock worth $8,418,000 after buying an additional 52,940 shares during the last quarter. Voya Investment Management LLC acquired a new position in shares of Revance Therapeutics during the second quarter worth approximately $274,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Revance Therapeutics by 13.1% during the second quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock worth $89,106,000 after buying an additional 391,638 shares during the last quarter. Institutional investors own 76.69% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Revance Therapeutics (RVNC) Stock Rating Lowered by Guggenheim” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2018/01/12/revance-therapeutics-rvnc-stock-rating-lowered-by-guggenheim.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.